Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Retraction: An MSN-PEG-IP drug delivery system and IL13Rα2 as targeted therapy for glioma
Jinlong
Shi
a,
Shiqiang
Hou
a,
Jianfei
Huang
c,
Shanshan
Wang
b,
Wei
Huan
a,
Chuanjun
Huang
a,
Xiaojiang
Liu
a,
Rui
Jiang
a,
Wenbo
Qian
a,
Jingjing
Lu
d,
Xiubing
Wang
e,
Wei
Shi
*a,
Rongqin
Huang
*b and
Jian
Chen
*a
aJiangsu Clinical Medicine Centre of Tissue Engineering and Nerve Injury Repair, Department of Neurosurgery, Affiliated Hospital of Nantong University, Nantong 226001, China. E-mail: ntshiwei123@163.com; ntfychenjian@126.com; Tel: +86 -513-8116-0802
bDepartment of Pathology, Clinical Bio-Bank, Affiliated Hospital of Nantong University, Nantong 226001, China
cDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, 826 Zhangheng Road, Shanghai 201203, China. E-mail: rqhuang@fudan.edu.cn; Tel: +86 -21-5198-0078
dResearch Centre of Clinical Medicine, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong 226001, China
eMedical Image Centre, Affiliated Hospital of Nantong University, Nantong 226001, China
First published on 7th February 2024
Abstract
Retraction of ‘An MSN-PEG-IP drug delivery system and IL13Rα2 as targeted therapy for glioma’ by Jinlong Shi et al., Nanoscale, 2017, 9, 8970–8981, https://doi.org/10.1039/C6NR08786H.
The Royal Society of Chemistry hereby wholly retracts this Nanoscale article due to concerns with the reliability of the data.
The fluorescence microscopy data in Fig. 2 and 3, the immunofluorescence data in Fig. 4a and the image data in Fig. 7e and Fig. 7g contain fully or partially overlapping panels.
In Fig. 2 there are overlapping sections between the panels for U87-shIL13Rα2 DAPI MP/D, U87-shIL13Rα2 DAPI MPI/D, C6-IL13α2 DAPI MP/D, and C6-shIL13Rα2 DAPI MP/D. There are overlapping sections between the panels for U87-shIL13Rα2 DOX MP/D, U87-shIL13Rα2 DOX MPI/D, C6-IL13α2 DOX MP/D, and C6-shIL13Rα2 DOX MP/D.
In Fig. 3a the panel for Liver M/D DOX has partial overlap with the panel for Liver MPI/D DOX. The panel for Liver M/D DAPI has partial overlap with the panel for Liver MPI/D DAPI. The panel for Spleen M/D DAPI has partial overlap with the panel for Spleen MPI/D DAPI. The panel for Lung M/D DAPI has partial overlap with the panel for Lung MPI/D DAPI. The panel for Spleen MPI/D DOX has partial overlap with the panel for Spleen M/D DOX. The authors have stated that the panel for Brain MPI/D DAPI is incorrect.
In Fig. 4a the panel for C6-IL13α2 Caspase-3 M/D has partial overlap with the panel for C6-IL13α2 Caspase MPI.
In Fig. 7e the panel for MPI U87 has partial overlap with the panel for MPI U87-shIL13Rα2.
In Fig. 7g the panel for U87 48 h IL13 is identical to the panels for U87 48 h IL13 + MPI and U87-shIL13Rα2 0 h MPI. The panel for U87 48 h Control is identical to the panels for U87-shIL13Rα2 48 h IL13 + MPI and U87-shIL13Rα2 48 h IL13. The panel for U87 48 h MPI is identical to the panel for U87-shIL13Rα2 48 h MPI. The panel for U87-shIL13Rα2 0 h IL13 is identical to the panel for U87-shIL13Rα2 0 h IL13 + MPI.
Given the multiple pieces of overlapping data, the findings presented in this paper are no longer reliable.
The authors were informed about the retraction of the article. Jian Chen and Jinlong Shi have not agreed with the decision. The other authors were contacted but have not responded.
Signed: Heather Montgomery, Managing Editor, Nanoscale
Date: 31st January 2024
| This journal is © The Royal Society of Chemistry 2024 |